| Cash Flow | 2026-06-30 |
|---|---|
| Royalty revenues-Royalty | 183 |
| Research and development-Repibresib VYN201 | 192 |
| Research and development-Research And Development Of VYN202 | 592 |
| Other segment items | 821 |
| General and administrative | 5,496 |
| Total operating expenses | 7,101 |
| Operating loss | -6,918 |
| Other income, net | 434 |
| Loss from continuing operations before income taxes | -6,484 |
| Income tax expense | 0 |
| Loss from continuing operations | -6,484 |
| Loss from discontinued operations, net of income taxes | -108 |
| Net loss | -6,592 |
| Depreciation | 12 |
| Stock-based compensation | 910 |
| Amortization of premium or discount on marketable securities | -21 |
| Prepaid expenses and other assets and operating lease right-of-use assets | -462 |
| Trade payables, accrued expenses, employee related obligations and other long-term liabilities | -844 |
| Operating lease liabilities | 0 |
| Net cash used in operating activities | -6,073 |
| Proceeds from sale and maturity of marketable securities | 5,000 |
| Purchases of marketable securities | 0 |
| Net cash provided by investing activities | 5,000 |
| Withholdings from exercise of options and issuance of shares for stock-based compensation arrangements, net | -29 |
| Net cash used in financing activities | -29 |
| (decrease) increase in cash and cash equivalents | -1,102 |
| Cash and cash equivalents at beginning of the period | 24,027 |
| Cash and cash equivalents at end of the period | 22,925 |
Yarrow Bioscience, Inc. (YARW)
Yarrow Bioscience, Inc. (YARW)